Farallon Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Farallon Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-800,000	Closed	-$41.3M	–	314
2022 Q3	$41.3M	Buy	+800,000	New	+$33.1M	0.23%	78
2022 Q1	–	Sell	-935,463	Closed	-$34.1M	–	347
2021 Q4	$34.1M	Buy	935,463 +549,463	+142%	+$19.3M	0.17%	78
2021 Q3	$6.6M	Buy	+386,000	New	+$6.01M	0.03%	172
2020 Q1	–	Sell	-1,500,000	Closed	-$59.3M	–	121
2019 Q4	$59.3M	Sell	1,500,000 -513,396	-25%	-$9.01M	0.4%	49
2019 Q3	$13.7M	Buy	2,013,396 +13,396	+0.7%	+$101K	0.1%	81
2019 Q2	$18.6M	Buy	2,000,000 +500,000	+33%	+$5.79M	0.12%	79
2019 Q1	$20.8M	Buy	1,500,000 +50,000	+3%	+$572K	0.16%	71
2018 Q4	$15.8M	Buy	1,450,000 +300,000	+26%	+$3.16M	0.12%	72
2018 Q3	$14.5M	Hold	1,150,000	–	–	0.09%	77
2018 Q2	$15.1M	Buy	1,150,000 +200,000	+21%	+$2.39M	0.09%	66
2018 Q1	$12.9M	Buy	+950,000	New	+$9.8M	0.09%	70

Other funds holding CCXI

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Farallon Capital Management's CCXI Position: Q4 2022 in Review

Farallon Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 800,000 shares — an estimated $41.3M sold.

Farallon Capital Management first reported a position in CCXI in Q1 2018 and held it in 11 quarters. The position peaked at $59.3M in Q4 2019. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.

Farallon Capital Management reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
Farallon Capital Management sold 800,000 ChemoCentryx, Inc. shares in Q4 2022, an estimated $41.3M.
Farallon Capital Management first reported a position in ChemoCentryx, Inc. in Q1 2018 and held it in 11 quarters.
Farallon Capital Management's ChemoCentryx, Inc. position peaked at $59.3M in Q4 2019.
1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.

Based on Farallon Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.